{"title":"AAV2 Vectors","description":"\u003cp\u003eReady-to-use AAV2 vectors for retinal and local CNS gene delivery — the benchmark serotype, qPCR-titered and in stock.\u003c\/p\u003e","products":[{"product_id":"aav-null-aav-serotype-2-bhv21500012","title":"AAV-Null (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500012\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165636461,"sku":"SL100811-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165669229,"sku":"SL100811-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500012_aav-null-aav-serotype-2_SL100811.jpg?v=1770796175"},{"product_id":"aav-gfp-aav-serotype-2-bhv21500013","title":"AAV-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500013\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165701997,"sku":"SL100812-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165734765,"sku":"SL100812-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500013_aav-gfp-aav-serotype-2_SL100812.png?v=1770796176"},{"product_id":"scaav-gfp-aav-serotype-2-self-complementary-bhv21500014","title":"scAAV-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500014\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165767533,"sku":"SL100812-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165800301,"sku":"SL100812-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500014_scaav-gfp-aav-serotype-2-self-complementary_SL100812-SC.png?v=1770796176"},{"product_id":"aav-cre-aav-serotype-2-bhv21500015","title":"AAV-Cre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500015\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165833069,"sku":"SL100813-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165865837,"sku":"SL100813-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500015_aav-cre-aav-serotype-2_SL100813.png?v=1770796176"},{"product_id":"scaav-cre-aav-serotype-2-self-complementary-bhv21500016","title":"scAAV-Cre (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500016\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165898605,"sku":"SL100813-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165931373,"sku":"SL100813-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500016_scaav-cre-aav-serotype-2-self-complementary_SL100813-SC.png?v=1770796176"},{"product_id":"aav-cre-gfp-aav-serotype-2-bhv21500017","title":"AAV-Cre-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500017\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165964141,"sku":"SL100814-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165996909,"sku":"SL100814-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500017_aav-cre-gfp-aav-serotype-2_SL100814.png?v=1770796177"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-2-bhv21500018","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500018\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166029677,"sku":"SL100815-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166062445,"sku":"SL100815-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500018_aav-u6-shrna-scramble-gfp-aav-serotype-2_SL100815.png?v=1770796177"},{"product_id":"aav-cag-gfp-aav-serotype-2-bhv21500019","title":"AAV-CAG-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500019\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166095213,"sku":"SL100816-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166127981,"sku":"SL100816-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500019_aav-cag-gfp-aav-serotype-2_SL100816.png?v=1770796178"},{"product_id":"aav-synapsin-gfp-aav-serotype-2-bhv21500020","title":"AAV-Synapsin-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500020\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166160749,"sku":"SL100817-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166193517,"sku":"SL100817-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500020_aav-synapsin-gfp-aav-serotype-2_SL100817.png?v=1770796178"},{"product_id":"scaav-synapsin-gfp-aav-serotype-2-self-complementary-bhv21500021","title":"scAAV-Synapsin-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500021\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166226285,"sku":"SL100817-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166259053,"sku":"SL100817-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500021_scaav-synapsin-gfp-aav-serotype-2-self-complementary_SL100817-SC.png?v=1770796178"},{"product_id":"aav-cag-chr2-venus-aav-serotype-2-bhv21500063","title":"AAV-CAG-ChR2-Venus (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChR2-Venus\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500063\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChR2-Venus is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChR2\u003c\/strong\u003e. A \u003cstrong\u003eVenus\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169240941,"sku":"SL100847-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169273709,"sku":"SL100847-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500063_aav-cag-chr2-venus-aav-serotype-2_SL100847.png?v=1770796192"},{"product_id":"aav-mrfp-aav-serotype-2-bhv21500069","title":"AAV-mRFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500069\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169634157,"sku":"SL100853-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169666925,"sku":"SL100853-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500069_aav-mrfp-aav-serotype-2_SL100853.png?v=1770796195"},{"product_id":"aav-lacz-aav-serotype-2-bhv21500070","title":"AAV-LacZ (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-LacZ\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500070\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLacZ is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: LacZ-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169699693,"sku":"SL100854-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169732461,"sku":"SL100854-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500070_aav-lacz-aav-serotype-2_SL100854.png?v=1770796195"},{"product_id":"aav-cag-chief-tdtomato-aav-serotype-2-bhv21500071","title":"AAV-CAG-ChIEF-tdTOMATO (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChIEF-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500071\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169765229,"sku":"SL100855-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169797997,"sku":"SL100855-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500071_aav-cag-chief-tdtomato-aav-serotype-2_SL100855.png?v=1770796195"},{"product_id":"aav-cag-cre-aav-serotype-2-bhv21500089","title":"AAV-CAG-Cre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500089\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171108717,"sku":"SL100884-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171141485,"sku":"SL100884-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500089_aav-cag-cre-aav-serotype-2_SL100884.png?v=1770796202"},{"product_id":"aav-u6-mirna-scramble-gfp-aav-serotype-2-bhv21500094","title":"AAV-U6-miRNA(Scramble)-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-miRNA(Scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500094\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emiRNA is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: miRNA-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171403629,"sku":"SL100889-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171436397,"sku":"SL100889-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500094_aav-u6-mirna-scramble-gfp-aav-serotype-2_SL100889.png?v=1770796204"},{"product_id":"aav-cag-cre-gfp-aav-serotype-2-bhv21500096","title":"AAV-CAG-Cre-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500096\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171534701,"sku":"SL100891-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171567469,"sku":"SL100891-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500096_aav-cag-cre-gfp-aav-serotype-2_SL100891.png?v=1770796204"},{"product_id":"aav-synapsin-tdtomato-aav-serotype-2-bhv21500101","title":"AAV-Synapsin-tdTOMATO (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500101\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003etdTOMATO is the encoded payload for this construct. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tdTOMATO-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171862381,"sku":"SL100896-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171895149,"sku":"SL100896-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500101_aav-synapsin-tdtomato-aav-serotype-2_SL100896.png?v=1770796205"},{"product_id":"aav-cag-chr2-h134r-tdtomato-aav-serotype-2-bhv21500102","title":"AAV-CAG-ChR2(H134R)-tdTOMATO (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChR2(H134R)-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500102\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChR2 (channelrhodopsin-2) is the classic optogenetic actuator for blue light-driven neuronal excitation. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171927917,"sku":"SL100897-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171960685,"sku":"SL100897-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500102_aav-cag-chr2-h134r-tdtomato-aav-serotype-2_SL100897.png?v=1770796206"},{"product_id":"aav-mcherry-aav-serotype-2-bhv21500159","title":"AAV-mCherry (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500159\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020175958381,"sku":"SL101405-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020175991149,"sku":"SL101405-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500159_aav-mcherry-aav-serotype-2_SL101405.png?v=1770796229"},{"product_id":"aav-cag-icre-aav-serotype-2-bhv21500161","title":"AAV-CAG-iCre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500161\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176089453,"sku":"SL101410-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176122221,"sku":"SL101410-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500161_aav-cag-icre-aav-serotype-2_SL101410.png?v=1770796229"},{"product_id":"aav-cag-flpo-aav-serotype-2-bhv21500166","title":"AAV-CAG-FLPo (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500166\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176417133,"sku":"SL101415-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176449901,"sku":"SL101415-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500166_aav-cag-flpo-aav-serotype-2_SL101415.png?v=1770796231"},{"product_id":"aav-cmv-hascpf1-aav-serotype-2-bhv21500169","title":"AAV-CMV-hAsCpf1 (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-hAsCpf1\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500169\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003ehAsCpf1 is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: hAsCpf1-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176613741,"sku":"SL101418-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176646509,"sku":"SL101418-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500169_aav-cmv-hascpf1-aav-serotype-2_SL101418.png?v=1770796232"},{"product_id":"aav-cmv-icre-aav-serotype-2-bhv21500172","title":"AAV-CMV-iCre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500172\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176810349,"sku":"SL101427-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176843117,"sku":"SL101427-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500172_aav-cmv-icre-aav-serotype-2_SL101427.png?v=1770796234"},{"product_id":"aav-syn-icre-aav-serotype-2-bhv21500186","title":"AAV-Syn-iCre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500186\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177760621,"sku":"SL101442-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177793389,"sku":"SL101442-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500186_aav-syn-icre-aav-serotype-2_SL101442.png?v=1770796238"},{"product_id":"aav-syn-flpo-aav-serotype-2-bhv21500192","title":"AAV-Syn-FLPo (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500192\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178153837,"sku":"SL101448-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178186605,"sku":"SL101448-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500192_aav-syn-flpo-aav-serotype-2_SL101448.png?v=1770796241"},{"product_id":"aav-cmv-flpo-aav-serotype-2-bhv21500200","title":"AAV-CMV-FLPo (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500200\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178678125,"sku":"SL101456-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178710893,"sku":"SL101456-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500200_aav-cmv-flpo-aav-serotype-2_SL101456.png?v=1770796243"},{"product_id":"aav-synapsin-cre-aav-serotype-2-bhv21500206","title":"AAV-Synapsin-Cre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500206\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179071341,"sku":"SL101462-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179104109,"sku":"SL101462-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500206_aav-synapsin-cre-aav-serotype-2_SL101462.png?v=1770796245"},{"product_id":"aav-cmv-luc-aav-serotype-2-bhv21500238","title":"AAV-CMV-Luc (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500238\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181201261,"sku":"SL101503-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181234029,"sku":"SL101503-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500238_aav-cmv-luc-aav-serotype-2_SL101503.png?v=1770796256"},{"product_id":"aav-hsyn-dio-gfp-aav-serotype-2-bhv21500246","title":"AAV-hSyn-DIO-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500246\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-GFP is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181725549,"sku":"SL101517-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181758317,"sku":"SL101517-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500246_aav-hsyn-dio-gfp-aav-serotype-2_SL101517.png?v=1770796259"},{"product_id":"aav-cmv-mcherry-t2a-luc-aav-serotype-2-bhv21500305","title":"AAV-CMV-mCherry-T2A-Luc (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-mCherry-T2A-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500305\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry-T2A-Luc is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-T2A-Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020185887085,"sku":"SL116063-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020185919853,"sku":"SL116063-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500305_aav-cmv-mcherry-t2a-luc-aav-serotype-2_SL116063.png?v=1770796280"},{"product_id":"aav-cag-luc-t2a-gfp-aav-serotype-2-bhv21500308","title":"AAV-CAG-Luc-T2A-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Luc-T2A-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500308\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuc-T2A-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-T2A-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020186083693,"sku":"SL116066-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020186116461,"sku":"SL116066-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500308_aav-cag-luc-t2a-gfp-aav-serotype-2_SL116066.png?v=1770796281"},{"product_id":"aav-cag-luc-aav-serotype-2-bhv21500317","title":"AAV-CAG-Luc (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500317\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020186673517,"sku":"SL116083-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020186706285,"sku":"SL116083-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500317_aav-cag-luc-aav-serotype-2_SL116083.png?v=1770796284"},{"product_id":"aav-mdlx-gfp-aav-serotype-2-bhv21500318","title":"AAV-mDLX-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mDLX-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003emDlx Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500318\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe mDlx promoter selectively drives expression in GABAergic interneurons, enabling cell-type-specific access to inhibitory populations. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emDLX-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression in GABAergic inhibitory interneurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mDLX-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020186739053,"sku":"SL116084-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020186771821,"sku":"SL116084-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500318_aav-mdlx-gfp-aav-serotype-2_SL116084.png?v=1770796284"},{"product_id":"aav-mdlx-mcherry-aav-serotype-2-bhv21500324","title":"AAV-mDLX-mCherry (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mDLX-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003emDlx Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500324\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe mDlx promoter selectively drives expression in GABAergic interneurons, enabling cell-type-specific access to inhibitory populations. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emDLX-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression in GABAergic inhibitory interneurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mDLX-mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020187132269,"sku":"SL116101-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020187165037,"sku":"SL116101-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500324_aav-mdlx-mcherry-aav-serotype-2_SL116101.png?v=1770796287"},{"product_id":"aav-syn-mcherry-aav-serotype-2-bhv21500326","title":"AAV-Syn-mCherry (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500326\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020187263341,"sku":"SL116103-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020187296109,"sku":"SL116103-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500326_aav-syn-mcherry-aav-serotype-2_SL116103.png?v=1770796287"},{"product_id":"aav-hsyn-hchr2-h134r-eyfp-serotype-2-bhv21500334","title":"AAV-hSyn-hChR2(H134R)-EYFP (Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-hChR2(H134R)-EYFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500334\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003ehChR2 (channelrhodopsin-2) is a light-gated cation channel for optogenetic activation of neurons. A \u003cstrong\u003eYFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020187918701,"sku":"SL116115-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020187951469,"sku":"SL116115-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500334_aav-hsyn-hchr2-h134r-eyfp-serotype-2_SL116115.png?v=1770796290"},{"product_id":"aav-empty-capsid-serotype-2-bhv21500361","title":"AAV Empty Capsid (Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV Empty Capsid\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eModerate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500361\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eEmpty Capsid is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cell-type targeting not specified; verify in your model.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Empty Capsid-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 Capsid\/mL \/ 30 uL (Std Pack)","offer_id":53020190769517,"sku":"SL116194-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 Capsid\/mL \/ 10 uL (Trial Pack)","offer_id":53020190802285,"sku":"SL116194-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AAV2_EMPTY.jpg?v=1779467723"},{"product_id":"aav-cag-icre-t2a-gfp-aav-serotype-2-bhv21500380","title":"AAV-CAG-iCre-T2A-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre-T2A-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500380\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre-T2A-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020192375149,"sku":"SL116274-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020192407917,"sku":"SL116274-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500380_aav-cag-icre-t2a-gfp-aav-serotype-2_SL116274.png?v=1770796309"},{"product_id":"aav-ef1a-mcherry-aav-serotype-2-bhv21500384","title":"AAV-EF1a-mCherry (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1a-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500384\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020192702829,"sku":"SL116303-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020192735597,"sku":"SL116303-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500384_aav-ef1a-mcherry-aav-serotype-2_SL116303.png?v=1770796311"},{"product_id":"aav-syn-null-aav-serotype-2-bhv21500400","title":"AAV-Syn-NULL (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-NULL\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500400\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020194046317,"sku":"SL116349-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020194079085,"sku":"SL116349-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500400_aav-syn-null-aav-serotype-2_SL116349.png?v=1770796316"},{"product_id":"aav-camkii-gfp-aav-serotype-2-bhv21500427","title":"AAV-CaMKII-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CaMKII-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500427\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020195979629,"sku":"SL116380-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020196012397,"sku":"SL116380-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500427_aav-camkii-gfp-aav-serotype-2_SL116380.png?v=1770796326"}],"url":"https:\/\/www.ebiohippo.com\/collections\/aav2-vectors.oembed","provider":"BioHippo","version":"1.0","type":"link"}